SG10201806465TA - Single-chain trail-receptor agonist proteins - Google Patents
Single-chain trail-receptor agonist proteinsInfo
- Publication number
- SG10201806465TA SG10201806465TA SG10201806465TA SG10201806465TA SG10201806465TA SG 10201806465T A SG10201806465T A SG 10201806465TA SG 10201806465T A SG10201806465T A SG 10201806465TA SG 10201806465T A SG10201806465T A SG 10201806465TA SG 10201806465T A SG10201806465T A SG 10201806465TA
- Authority
- SG
- Singapore
- Prior art keywords
- trail
- receptor agonist
- agonist proteins
- proteins
- chain trail
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 229940123369 TRAIL receptor agonist Drugs 0.000 title abstract 4
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 abstract 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 abstract 2
- 108700012411 TNFSF10 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 abstract 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 abstract 1
- 230000004931 aggregating effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983152P | 2014-04-23 | 2014-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201806465TA true SG10201806465TA (en) | 2018-08-30 |
Family
ID=53055121
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201806465TA SG10201806465TA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
| SG10202111785VA SG10202111785VA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
| SG11201608767XA SG11201608767XA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111785VA SG10202111785VA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
| SG11201608767XA SG11201608767XA (en) | 2014-04-23 | 2015-04-23 | Single-chain trail-receptor agonist proteins |
Country Status (38)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3292143B1 (en) * | 2015-05-04 | 2019-08-21 | Apogenix AG | Single-chain cd40-receptor agonist proteins |
| JP6959229B2 (ja) * | 2015-10-23 | 2021-11-02 | アポジェニックス アーゲー | 一本鎖ｇｉｔｒ受容体アゴニストタンパク質 |
| WO2017068192A1 (en) | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain cd27-receptor agonist proteins |
| WO2017068180A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain light receptor agonist proteins |
| WO2017102010A1 (en) * | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| CN109153711B (zh) * | 2016-03-01 | 2022-04-26 | 伊利诺伊大学理事会 | 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白 |
| WO2017161173A1 (en) * | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
| US10501744B2 (en) | 2016-05-04 | 2019-12-10 | Indiana University Research And Technology Corporation | Presentation of bioactive proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP2019517570A (ja) * | 2016-06-13 | 2019-06-24 | メリマック ファーマシューティカルズ インコーポレーティッド | Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法 |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| CN111050784B (zh) * | 2017-08-11 | 2024-03-19 | 伊利诺伊大学理事会 | 截短的豚鼠l-天冬酰胺酶变体及其使用方法 |
| TW202003553A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療癌症之abbv-621與抗癌劑之組合 |
| TW202002952A (zh) | 2018-03-15 | 2020-01-16 | 美商艾伯維有限公司 | 用於治療胰臟癌之abbv-621與抗癌劑之組合 |
| EP4149964A2 (en) | 2020-05-15 | 2023-03-22 | Apogenix AG | Multi-specific immune modulators |
| AU2022281108A1 (en) | 2021-05-28 | 2023-12-14 | Julius-Maximilians-Universität Würzburg | Recombinant proteinaceous binding molecules |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025277A1 (en) | 1999-10-07 | 2001-04-12 | Maxygen Aps | Single-chain antagonist polypeptides |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| UA93662C2 (uk) * | 2000-12-07 | 2011-03-10 | Эли Лилли Энд Компани | Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| WO2003091447A2 (en) | 2002-04-26 | 2003-11-06 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| US20060188498A1 (en) * | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
| MX2007010484A (es) | 2005-04-15 | 2007-10-15 | Rappaport Family Inst For Res | Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2. |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| CA2692802C (en) | 2007-07-10 | 2017-05-30 | Oliver Hill | Tnf superfamily collectin fusion proteins |
| JP2011523853A (ja) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
| ES2571879T3 (es) | 2008-07-21 | 2016-05-27 | Apogenix Ag | Moléculas de una sola cadena de TNFSF |
| US20110287001A1 (en) | 2008-09-22 | 2011-11-24 | Tetralogic Pharmaceuticals | Method of treatment |
| EP2379585A2 (en) * | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
| JP5844158B2 (ja) | 2009-01-09 | 2016-01-13 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | 三量体形成融合タンパク質 |
| WO2010085682A2 (en) * | 2009-01-23 | 2010-07-29 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| JP2013514795A (ja) * | 2009-12-22 | 2013-05-02 | ノバルティス アーゲー | 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質 |
| ES2755398T3 (es) | 2010-04-13 | 2020-04-22 | Medimmune Llc | Andamios multiméricos específicos de TRAIL R2 |
| EP2793947B1 (en) * | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| HK1207095A1 (en) | 2012-07-18 | 2016-01-22 | 阿珀吉尼科斯股份公司 | Composition comprising a mixture of cd95-fc isoforms |
-
2012
- 2012-11-06 NO NO12790406A patent/NO2776305T3/no unknown
-
2015
- 2015-04-23 CR CR20160516A patent/CR20160516A/es unknown
- 2015-04-23 SG SG10201806465TA patent/SG10201806465TA/en unknown
- 2015-04-23 ES ES15721089.9T patent/ES2672368T3/es active Active
- 2015-04-23 LT LTEP15721089.9T patent/LT3134430T/lt unknown
- 2015-04-23 EP EP18155146.6A patent/EP3366699A1/en not_active Withdrawn
- 2015-04-23 PT PT157210899T patent/PT3134430T/pt unknown
- 2015-04-23 CN CN201580031858.7A patent/CN106459221B/zh not_active Expired - Fee Related
- 2015-04-23 PH PH1/2020/500377A patent/PH12020500377A1/en unknown
- 2015-04-23 JP JP2016564068A patent/JP6523331B2/ja not_active Expired - Fee Related
- 2015-04-23 HR HRP20180950TT patent/HRP20180950T1/hr unknown
- 2015-04-23 UA UAA201611802A patent/UA118286C2/uk unknown
- 2015-04-23 DK DK15721089.9T patent/DK3134430T3/en active
- 2015-04-23 MX MX2016013858A patent/MX2016013858A/es active IP Right Grant
- 2015-04-23 RS RS20180450A patent/RS57153B1/sr unknown
- 2015-04-23 PL PL15721089T patent/PL3134430T3/pl unknown
- 2015-04-23 AU AU2015249649A patent/AU2015249649B2/en not_active Ceased
- 2015-04-23 US US14/694,358 patent/US9908927B2/en active Active
- 2015-04-23 SG SG10202111785VA patent/SG10202111785VA/en unknown
- 2015-04-23 RU RU2016145608A patent/RU2699285C2/ru active
- 2015-04-23 SI SI201530223T patent/SI3134430T1/en unknown
- 2015-04-23 TR TR2018/06912T patent/TR201806912T4/tr unknown
- 2015-04-23 WO PCT/US2015/027270 patent/WO2015164588A1/en not_active Ceased
- 2015-04-23 UY UY0001036095A patent/UY36095A/es active IP Right Grant
- 2015-04-23 SG SG11201608767XA patent/SG11201608767XA/en unknown
- 2015-04-23 KR KR1020197035100A patent/KR20190135546A/ko not_active Ceased
- 2015-04-23 HU HUE15721089A patent/HUE038914T2/hu unknown
- 2015-04-23 CN CN202010767219.XA patent/CN111718424A/zh active Pending
- 2015-04-23 CA CA2946402A patent/CA2946402C/en active Active
- 2015-04-23 EP EP15721089.9A patent/EP3134430B1/en active Active
- 2015-04-23 MA MA039770A patent/MA39770A/fr unknown
- 2015-04-23 MY MYPI2016703814A patent/MY181986A/en unknown
- 2015-04-23 TW TW104113087A patent/TWI683825B/zh not_active IP Right Cessation
- 2015-04-23 SM SM20180286T patent/SMT201800286T1/it unknown
- 2015-04-23 KR KR1020167032819A patent/KR102079919B1/ko not_active Expired - Fee Related
- 2015-04-23 BR BR112016024515-6A patent/BR112016024515B1/pt not_active IP Right Cessation
- 2015-04-23 MA MA045069A patent/MA45069A/fr unknown
- 2015-04-23 AR ARP150101224A patent/AR100168A1/es active IP Right Grant
- 2015-04-23 CA CA3184067A patent/CA3184067A1/en active Pending
- 2015-04-23 TW TW109106778A patent/TWI747178B/zh not_active IP Right Cessation
- 2015-04-23 PE PE2016002016A patent/PE20170299A1/es unknown
-
2016
- 2016-10-07 IL IL248244A patent/IL248244B/en active IP Right Grant
- 2016-10-19 DO DO2016000284A patent/DOP2016000284A/es unknown
- 2016-10-19 PH PH12016502079A patent/PH12016502079B1/en unknown
- 2016-10-21 CL CL2016002683A patent/CL2016002683A1/es unknown
- 2016-10-21 MX MX2019013587A patent/MX2019013587A/es unknown
- 2016-11-23 EC ECIEPI201689579A patent/ECSP16089579A/es unknown
-
2018
- 2018-02-02 US US15/887,509 patent/US20180222962A1/en not_active Abandoned
- 2018-05-25 CY CY20181100568T patent/CY1120281T1/el unknown
- 2018-11-30 AU AU2018271369A patent/AU2018271369B2/en not_active Ceased
-
2019
- 2019-04-24 JP JP2019082671A patent/JP6714751B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 IL IL272612A patent/IL272612A/en unknown
- 2020-03-30 AU AU2020202247A patent/AU2020202247A1/en not_active Abandoned
- 2020-08-14 US US16/993,569 patent/US20210040178A1/en not_active Abandoned
-
2023
- 2023-07-14 US US18/352,769 patent/US20240174731A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/892,964 patent/US20250145688A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013587A (es) | Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual. | |
| MX2017014140A (es) | Proteinas agonistas receptoras cd40 de cadena simple. | |
| IL278014A (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| EP3679071A4 (en) | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | |
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
| MX2018001787A (es) | Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas. | |
| DK3180018T3 (da) | Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein | |
| UA117045C2 (uk) | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування | |
| MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
| IL276616A (en) | Dosage for treatment with IL-22 Fc fusion proteins | |
| EA202091567A1 (ru) | Химерные белки мти | |
| WO2016007919A3 (en) | Antibody fragments for detecting cancer and methods of use | |
| EP3925979A3 (en) | Fgfr-tacc fusion proteins and methods thereof | |
| EP3227681A4 (en) | Anti-acetaminophen antibodies and acetaminophen protein adducts | |
| EP3147361A4 (en) | Fusion protein suitable for measurement of autophagy, nucleic acid encoding said fusion protein, and use of these | |
| EA201992348A1 (ru) | АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1 | |
| NZ761611A (en) | Single-chain trail-receptor agonist proteins | |
| TH1701003441A (th) | แอนติ-ไมโอสแตตินแอนติบอดี, โพลีเปปไทด์ที่ประกอบด้วยบริเวณแวเรียน Fc และวิธีการของการใช้ | |
| EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
| HUP1400447A2 (hu) | Fehérje multimerek specifikus detektálására alkalmas szendvics-ELISA egymással kompetálható antitestek használatával |